Mania News and Research

RSS

Schering-Plough submits response to FDA for SAPHRIS (asenapine) in the acute treatment of schizophrenia and bipolar I disorder

Schering-Plough Corporation has announced that it has responded to the U.S. Food and Drug Administration (FDA) complete response letter for SAPHRIS (asenapine) sublingual tablets, which was received in January 2009.

22 Feb 2009

New treatment approach needed for management of depression with bipolar disorder

In a study published in The American Journal of Psychiatry, a team of researchers led by Mayo Clinic psychiatrist Mark Frye, M.D., attempted to identify what factors make some people with bipolar depression more likely to experience treatment-emergent mania (TEM).

15 Feb 2009

Bipolar disorders linked to increased risk of early death from medical illness

Bipolar disorders appear to increase the risk of early death from a medical illness, according to a literature review study published as the lead article this week in the journal Psychiatric Services.

2 Feb 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

FDA issues complete response letter for SAPHRIS (asenapine) sublingual tablets in acute treatment of schizophrenia and bipolar disorder

Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.

15 Jan 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections

Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.

13 Nov 2008

Researchers say bipolar disorder also afflicts children

A study by researchers in the United States has found that bipolar disorder also afflicts children.

13 Oct 2008

Older fathers more likely to have children with bipolar disorder

According to new research by Swedish scientists, older fathers are more likely to have children with bipolar disorder.

2 Sep 2008

Children of older fathers more likely to have bipolar disorder

Older age among fathers may be associated with an increased risk for bipolar disorder in their offspring, according to a report in the September issue of Archives of General Psychiatry.

1 Sep 2008

Using genetics to improve traditional psychiatric diagnoses

Psychiatry has begun the laborious effort of preparing the DSM-V, the new iteration of its diagnostic manual. In so doing, it once again wrestles with the task set by Carl Linnaeus, to "cleave nature at its joints." However, these "joints," the boundaries between psychiatric disorders, such as that between bipolar disorder and schizophrenia, are far from clear. Prior versions of DSM followed the path outlined by Emil Kraeplin in separating these disorders into distinct categories. Yet, we now know that symptoms of bipolar disorder may be seen in patients with schizophrenia and the reverse is true, as well.

17 Jul 2008

Watson Pharmaceuticals launches generic version of dronabinol

Watson Pharmaceuticals, Inc. has announced that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths.

30 Jun 2008

Long term dope use shrinks the brain

According to Australian researchers the long term use of marijuana may cause parts of the brain which control memory, emotion and aggression, to shrink.

3 Jun 2008

Long-term, heavy cannabis use may shrink brain's hippocampus and amygdala

Long-term, heavy cannabis use may be associated with structural abnormalities in areas of the brain known as the hippocampus and amygdala, according to a report in the June issue of Archives of General Psychiatry.

2 Jun 2008

Antipsychotic drugs dangerous for the elderly

A Canadian study has found that prescribing antipsychotic drugs for elderly people may be dangerous.

27 May 2008

Omega-3 fatty acids for bipolar disorder

Despite intriguing findings that omega-3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega-3s are useful treatments for people with bipolar disorder, according to a review of recent studies.

22 Apr 2008

How hormone levels affect financial traders

When City traders have high morning testosterone levels they make more than average profits for the rest of that day, researchers at the University of Cambridge have discovered.

15 Apr 2008

New mouse model of bipolar disorder

Bipolar Disorder (BPD or manic-depressive illness) is one of the most serious of all mental disorders, affecting millions of individuals worldwide.

13 Mar 2008

Tamoxifen may help treat mania in patients with bipolar disorder

A small, three-week trial of tamoxifen, a drug typically used to treat breast cancer, indicates that it also may decrease symptoms of mania in patients with bipolar disorder, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008